D. E. Shaw & Co., Inc. Igm Biosciences, Inc. Transaction History
D. E. Shaw & Co., Inc.
- $98.6 Billion
- Q2 2024
A detailed history of D. E. Shaw & Co., Inc. transactions in Igm Biosciences, Inc. stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 131,065 shares of IGMS stock, worth $1.34 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
131,065
Previous 93,163
40.68%
Holding current value
$1.34 Million
Previous $899,000
0.11%
% of portfolio
0.0%
Previous 0.0%
Shares
15 transactions
Others Institutions Holding IGMS
# of Institutions
87Shares Held
21.4MCall Options Held
39.5KPut Options Held
16.5K-
Baker Bros. Advisors LP New York, NY4.09MShares$41.9 Million0.37% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD4.08MShares$41.8 Million0.0% of portfolio
-
Artal Group S.A. Luxembourg, N43.33MShares$34.1 Million1.45% of portfolio
-
Redmile Group, LLC San Francisco, CA3.07MShares$31.5 Million1.38% of portfolio
-
Goldman Sachs Group Inc New York, NY1.33MShares$13.7 Million0.0% of portfolio
About IGM Biosciences, Inc.
- Ticker IGMS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 28,969,000
- Market Cap $297M
- Description
- IGM Biosciences, Inc., a biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. The company's lead product candidate is IGM-2323, a bispecific IgM antibody that is in Phase 2 clinical trials to treat patients with relapsed/refractory B cell Non...